The clinical trial, NCT05008575, currently underway at the Hematology Department of Chongqing Xinqiao Hospital in China targets leukemia cells expressing CD33, employing CAR-NK cells in combination with chemotherapy drugs (Table 1). Here, CD33 is linked to leukemia.